Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US. (Q40824160)
Jump to navigation
Jump to search
scientific article published on 18 June 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US. |
scientific article published on 18 June 2015 |
Statements
1 reference
Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US. (English)
1 reference
Ipek Özer Stillman
Stephanie Chen
Denis Getsios
Irina Proskorovsky
Luis Hernandez
18 June 2015
1 reference